Overview

Drug discovery aims to find and develop molecules that act on disease-relevant targets or biological processes, while balancing efficacy, safety, and the ability to make them. AI methods include graph and 3D models for predicting molecular properties, binding, and toxicity; generative models for proposing or editing molecules; and knowledge graphs and omics models for prioritizing targets and interpreting biological responses. Search and design methods increasingly combine these predictions with docking, synthesis constraints, experimental data, and tools coordinated by AI agents. A central challenge is that strong results on standard benchmarks may not transfer to unseen targets, chemistry, or assays, and computational scores still need reliable experimental validation.

Latest papers

178 papers15 papers in the last four weeks, down 37% on the four weeks before. 0.1% of all new papers.

Oct 5, 2026

Few-Shot Bioactivity Prediction with Meta-Learning under Assay Heterogeneity

Accurate bioactivity prediction is a central challenge in early-stage drug discovery, as individual assays often contain too few measurements to train reliable models independently. Meta-learning offers a principled approach to this few-shot setting, but assay heterogeneity may limit its effectiveness. Here, we test this hypothesis and show that meta-learning performance degrades as meta-training tasks become more heterogeneous. To address this, we introduce MetaHeta, a meta-learning framework that accounts for assay heterogeneity by conditioning predictions on auxiliary data from related assays, with relatedness defined flexibly from available assay information. The architecture of MetaHeta combines linear attention over large auxiliary datasets with exact attention over scarce task-specific context, enabling efficient scaling to the former without compromising exact attention over the latter. We demonstrate the benefits of our approach on assays from ChEMBL and BindingDB, improving few-shot bioactivity prediction and downstream compound prioritization in retrospective Bayesian optimization.
Oct 4, 2026

PharmAgent: Constraint-Aware Search with Frozen Language Models for Molecular Optimization

Molecular optimization must improve target activity and satisfy developability constraints within limited evaluation budgets. Classical methods require tailored rules or training to incorporate chemical instructions and property feedback. Frozen language models can condition edits on this information, but need explicit constraint control and relevant experience. We therefore present PharmAgent, a constraint-aware molecular search method driven by adaptive external state. Its Lagrangian controller translates violations in accepted states into accumulated constraint pressure, keeping this history separate from current property measurements. Structure-indexed replay complements this feedback with relevant evaluated transitions that guide subsequent proposals. As a curriculum progressively activates constraints, candidates and the incumbent are compared under the same current objective, and the accepted state determines the next multiplier update. We derive an exact identity that characterizes how accepted-state violations accumulate in the controller's multipliers. Across five tasks with five independent runs, PharmAgent achieves a summed area under the target-score curves (AUC) of 3.9208 in target-only search, improving over MOLLEO by 37.3%. With online constraints, it achieves a property-adjusted AUC of 0.7076, improving over the strongest online baseline, ExLLM, by 53.8%. These results rank first among all evaluated methods in both target-only and constraint-aware search. The online comparison covers all five baseline frameworks. The full system leads every ablation variant in target quality, property-adjusted performance, and Pareto hypervolume. All five molecular cases reach feasible final states, documenting target gains and trade-offs.
Oct 3, 2026

Toward a Locally Deployable Agentic Co-Scientist: Small-Model Planning for Early-Stage Drug Discovery

Early-stage computational drug discovery requires coordinating heterogeneous scientific tools across multi-step workflows. We present a lightweight, tool-augmented framework in which a locally deployable compact language model plans calls to 18 modular tools. A Unified Molecular Schema maintains shared molecular records, while a plug-in interface supports tool replacement and extension. We construct 1,263 manually refined query-plan pairs through workflow-graph path coverage and apply LoRA fine-tuning to three compact model families. Under the query-level split, all fine-tuned models generate fully parseable and schema-compliant plans on 47 held-out cross-group queries. Llama 3.2-3B achieves a tool-selection F1 of 0.998, sequence exact match of 0.979, and argument F1 of 0.960. Under the stricter workflow-grouped split, which excludes identical ordered tool sequences across partitions, sequence exact match reaches 0.452 to 0.548, highlighting the remaining difficulty for compact models in generating complete workflow paths unseen during training. These results demonstrate the feasibility of compact, locally deployable planning while identifying compositional generalization as an important direction for further improvement.
Oct 2, 2026

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.
Sep 30, 2026

R-GroundBench: A Diagnostic Benchmark for R-Group Groundingin Markush Molecular Editing

Recent advances in AI for scientific discovery enable molecular understandingand design, yet reasoning over incomplete chemical representations remainsunclear.Markush structures, which encode molecular families through variable R-groupplaceholders (R\textsubscript{1}, R\textsubscript{2}, X, etc.), are ubiquitous in pharmaceutical patents and requiregrounding across molecular, textual, and chemical information.However, existing molecule-language benchmarks focus on fully specifiedmolecules, leaving R-group grounding largely unevaluated.We introduce R-GroundBench:, a diagnostic benchmark built from real patent Markushstructures, featuring a Multiple-Choice (VQA) track with controlled difficultyand modality splits, and an open-ended Generation track.Our results reveal a substantial gap between recognition andmolecular grounding.While models achieve over 90% accuracy on Easy VQA, performance drops to56--66% on Hard VQA when shortcuts are controlled.Chemical-domain VLMs also remain unreliable, achieving only 25.7--46.2% on HardVQA despite domain-specific pretraining.Moreover, Generation Exact Match remains below 20% for most models and below8% when visual input is required.These findings reveal that current AI systems lack reliable grounding andexecution for Markush editing, highlighting challenges for AI-drivenscientific discovery.
Sep 29, 2026

Benchmarking graph-based models for in-silico toxicity prediction in drug discovery

Drug discovery is a costly and high-risk process, where toxicity-related failures remain a major cause of attrition in both preclinical and clinical stages. As a result, accurate early prediction of chemical toxicity is essential to reduce downstream costs and improve compound prioritization. In this context, graph deep learning (GDL) has emerged as a powerful paradigm for toxicity prediction, leveraging molecular graph representations to learn directly from chemical structure with improved expressivity over traditional approaches. Despite the growing number of proposed models, current literature-based comparisons are often difficult to interpret due to inconsistencies in datasets, preprocessing pipelines, and evaluation protocols. To address this limitation, we introduce a unified and standardized benchmarking framework for GDL-based toxicity prediction. We systematically evaluate more than 20 representative approaches under consistent experimental conditions and across multiple datasets and partitioning strategies, enabling a fair and reproducible comparison of model performance. In addition, we complement this empirical study with a structured literature analysis to contextualize existing methodological trends and performance claims. Our results provide a clearer and more reliable assessment of the current state of the field, highlighting both the strengths and limitations of existing graph-based approaches. To support transparency and reproducibility, we release our benchmarking framework as open-source software https://gitlab.citius.gal/noel.suarez/benchtox, allowing the community to evaluate and compare models under consistent conditions.
Sep 24, 2026

TopU-LBVS: A Realistic Multi Target Benchmark for Ligand Based Virtual Screening

Ligand-based virtual screening (LBVS) is a practical first-pass tool in early-stage drug discovery, but existing benchmarks can overestimate performance through random negatives, easy decoys, limited target coverage, and non-standardized evaluation protocols. We introduce TopU-LBVS, a multi-target benchmark for LBVS under hard-negative screening conditions. Starting from curated ChEMBL~35 bioactivity data, TopU-LBVS covers 93 protein targets across 7 protein classes and constructs target-specific screening libraries with property-matched, structurally similar decoys at a fixed 1:40 active-to-decoy ratio. Libraries contain roughly 400 to 10,000 compounds and are designed to reduce simple physicochemical and nearest-neighbor fingerprint shortcuts. TopU-LBVS provides three fixed protocols. TopU-LBVS-full evaluates ChEMBL∗→^\ast \rightarrow TopU generalization across all 93 targets. TopU-LBVS-low evaluates low-data TopU →\rightarrow TopU learning within the hard-negative distribution. TopU-LBVS-mini provides a compact seven-target protocol with a paired random-decoy control that changes only the test decoys, enabling low-cost development and direct measurement of the gap between random ChEMBL∗^\ast and TopU decoys. Across ten reference baselines spanning fingerprint methods, molecular GNNs, fingerprint hybrids, and modern molecular models, performance under random-decoy evaluation degrades sharply under hard-negative screening. We release data, fixed splits, evaluation code, and baseline implementations for reproducible comparison of future LBVS and molecular representation learning methods. Code and data are available at https://github.com/topu-benchmark/topu-lbvs and https://huggingface.co/datasets/topu-benchmark/topu-lbvs.
Sep 23, 2026

OPDiv: Optimal Selection of Top-K High-Scoring, Diverse Compounds

A virtual screening campaign may produce thousands of promising candidates, but only a small number can be purchased, synthesized, or tested. The practical question is how to select a set of compounds that both rank well and are diverse enough: this poses a genuine tradeoff, where selecting the highest-scoring molecules yields limited diversity, while diversity selection sacrifices some well-scoring molecules. We introduce OPDiv, a diversity selection and evaluation algorithm solving this tradeoff by finding an optimal subset of molecules using integer optimization. We demonstrate the selection algorithm in practice with fingerprint distance, shape and electrostatic diversity and compare the resulting diversity spectra. We argue that virtual screening is not merely a ranking problem, but also an implicit constrained optimization task: when redundant chemotypes are undesirable, pipelines should be compared based on the top-k compound selections satisfying the desired diversity constraints. OPDiv makes it possible to find the optimal compound set under a given diversity threshold efficiently and serves as a fair benchmark of the best diverse selection achievable by a given structure-based or ligand-based virtual screening pipeline, molecular search or generative model.
Sep 21, 2026

Adapting Boltz-2 with limited experimental activity data improves early enrichment in virtual screening

Virtual screening aims to prioritize active compounds from large chemical libraries within a limited experimental budget. When applying Boltz-2 to virtual screening, a key challenge is how to use limited experimental data from the target assay to improve the prioritization of active compounds. We investigated whether fine-tuning the Boltz-2 affinity heads with a small number of binary activity labels could improve early enrichment of active compounds in hit discovery. We compared fine-tuning with 40-300 labels in a retrospective evaluation on eight MF-PCBA targets. With 300 activity measurements, fine-tuning increased the number of actives in the top 1% by a geometric mean of 1.77-fold across the eight targets and improved average precision (AP) by 2.14-fold relative to the control without fine-tuning. We also investigated whether rescoring a subset of candidates could retain the improvement in hit recovery by reranking only the top-ranked Boltz-2 candidates with the fine-tuned head. Restricting rescoring to approximately 10% of the evaluation set retained hit recovery comparable to full rescoring. These findings show that affinity-head fine-tuning with limited activity labels improves early enrichment with Boltz-2 and that this benefit can be retained when rescoring a restricted set of candidates.
Sep 19, 2026

CurvFlow-DTA: dual-graph discrete Ricci curvature flow for drug--target affinity prediction

Graph neural networks are widely used for drug--target affinity (DTA) prediction, and discrete Ricci curvature has recently been used to characterize molecular graph geometry. Existing curvature-aware DTA approaches mainly use static curvature on the drug graph while representing proteins primarily with sequence-derived features. This leaves pair-adaptive use of graph geometry underexplored, which may limit adaptation to unseen entities in cold-start settings relevant to practical screening. We present CurvFlow-DTA, which replaces a single static curvature representation with weighted Forman curvature flow on both molecular and protein residue--residue contact graphs. A label-independent flow trajectory is precomputed for each entity, and a pair-conditioned selector determines the horizons read by a dual-branch Flow-GINE. A frozen ESM-2 supplies residue-level representations and contact scores used to construct the protein graph. Inference requires only SMILES strings and protein sequences, without a bound complex structure. On Davis and KIBA, CurvFlow-DTA improves on the protocol-matched Ricci-GraphDTA baseline in every warm and cold-start setting. Warm-split mean squared error (MSE) decreases by 19.9%19.9\% on Davis and 18.9%18.9\% on KIBA. Across the six cold-start comparisons, MSE decreases by 14.314.3--27.4%27.4\%, with higher concordance index (CI) throughout. Within our compiled set of literature baselines, CurvFlow-DTA achieves the lowest MSE on both warm benchmarks and across four out of six cold-start evaluation settings.
Sep 18, 2026

MIRCID: Inferred Hub-miRNAs Drive Cross-Task Improvements in Drug Mechanistic Modeling

Drug mechanism-of-action (MoA) modeling commonly relies on perturbational transcriptomes, but matched microRNA (miRNA) measurements are often unavailable. Inferred regulatory features offer a scalable way to reuse these data. Here, we present MIRCID, a framework comparing gene expression with inferred transcription factor (TF) activity and miRNA expression across pathway classification and similarity-based MoA retrieval. HubmiRNet infers 414 pan-cancer hub miRNAs (HubmiRs) from 977 L1000 landmark genes, achieving a Pearson correlation coefficient of 87.72%; its 1,298-output variant also outperformed SiCmiR on the full-miRNA task (71.21% versus 67.30%). In the evaluated comparisons, miRNA augmentation provided more consistent gains than TF activity. Generic embedding controls showed model-dependent utility, while complementarity analyses identified a distinct, partially linearly recoverable representation that retained gene-derived structure. Illustrative rescue cases linked improved classification to biologically plausible miRNA patterns in samples with weak transcriptional signatures. These findings support inferred HubmiRs as a biologically informed recoding of transcriptomic data for perturbational drug modeling, while leaving recovery of measured perturbational miRNA responses to further validation.
Sep 16, 2026

Evidence-Grounded Agentic Formulation Development in an Autonomous Laboratory

Self-emulsifying drug delivery systems (SEDDS) can improve the oral bioavailability of poorly soluble drugs, but identifying high-performing formulations remains experimentally intensive. We present Andromeda 2, an agentic system that reasons over structured in-house experimental evidence and invokes computational and experimental tools to design and execute successive formulation batches. Using a miniaturized automated laboratory at a matched budget, we benchmark it against Andromeda 1, a probabilistic optimization model deployed across dozens of live development projects, and a wet-lab design-of-experiments (DoE) campaign. For paclitaxel, Andromeda 2 achieved a 50% high-performance hit rate versus 17% for Andromeda 1 and 2% for DoE, and identified 12 formulations meeting all four target product profile (TPP) objectives versus 6 and 0, respectively. Median AUC10−240AUC_{10-240} was 70.1, 12.0, and 3.5 mg⋅\cdotmin/mL, while maximum AUC was comparable between Andromeda 2 and Andromeda 1. A selected full-TPP formulation achieved an apparent effective paclitaxel loading of 19±5%19 \pm 5\% w/w at the first FaSSIF measurement, approximately 3.3-fold higher than the 5.7% w/w loading reported for a published paclitaxel S-SEDDS. A controlled ablation showed that access to structured in-house experimental evidence increased mean AUC by 34%.
Sep 9, 2026

A Systematic Evaluation of Molecule Generation Models for De Novo Drug Design: From Benchmarks to Practical Insights

Molecule generation has emerged as a powerful computational tool for de novo drug design, enabling the exploration of chemical space beyond the limits of conventional virtual screening. The field has progressed rapidly, driven by advances in molecular representations, generative architectures, and target-aware modeling strategies. However, existing reviews typically address specific model families or application scenarios in isolation, rather than offering an integrated perspective on how these components collectively form a coherent generation workflow. In this review, we present a comprehensive evaluation of molecule generation models for de novo drug design, covering 82 methods across five deep generative frameworks, including recurrent neural network (RNN)- and Transformer-based models, variational autoencoders (VAEs), generative adversarial networks (GANs), flow-based models, and diffusion models. We first summarize widely used benchmarks and molecular representations, and then examine the methodological principles underlying both general and pocket-conditioned generation. A central contribution of this work is a systematic synthesis and comparative analysis of reported performance across commonly used benchmarks and evaluation metrics. We also summarize representative experimentally validated case studies. Looking ahead, we discuss future directions in standardized 3D data, interaction-aware generation, receptor flexibility, and multi-objective molecular design, with the aim of improving the reliability and experimental relevance of molecule generation. All collected benchmark resources, evaluation metrics, and model references are provided in a publicly accessible repository at https://github.com/JacklinGroup/molecule-generation-review.
Sep 4, 2026

Training Large Language Models for Small-Molecule Design with Synthetic Task Scaling

Designing viable drug candidates requires searching a combinatorially large and rugged chemical space for molecules that satisfy multiple, often competing, objectives. Large language models (LLMs) provide a useful generative prior for this problem because of their representational capacity, reasoning ability, and flexibility when incorporating information from the external environment. While reinforcement learning from verifiable rewards (RLVR) can be used to improve the capabilities of LLMs, many chemically relevant scoring functions require hours or even days per evaluation, making them prohibitively expensive to use directly during online training. Here, we investigate whether LLMs can learn molecular design strategies from cheaper synthetic tasks that generalize to expensive molecular lead optimization settings. We find that curriculum-based training recipes that gradually incorporate more challenging synthetic design tasks enable strong performance that surpasses that of much larger frontier models on structure-based lead optimization. Our results suggest that scaling post-training using synthetic tasks is an effective strategy for adapting LLMs to high-cost experimental scenarios that are too expensive to directly train on.
Sep 2, 2026

ProbeMatchDTI: Probe-Driven Multi-Scale Biochemical Pattern Matching for Drug-Target Interaction Prediction

Drug-target interaction (DTI) prediction is an important task in AI-driven drug discovery. Although recent biochemical representation learning methods have improved DTI prediction, their passive feature aggregation tends to favor dominant molecular patterns while suppressing weak yet binding-relevant signals, such as functional groups and residue-context patterns, limiting the modeling of multi-scale biochemical correspondences. To address this issue, we propose ProbeMatchDTI, a pattern-probe-driven framework comprising IterProbe and BindingProbe. IterProbe explicitly retains contextual states across refinement depths and uses learnable probes to select them at each position before cross-entity matching, thereby preserving weak biochemical patterns and strengthening associations among functional groups, local motifs, and molecular scaffolds. BindingProbe then characterizes cross-entity drug-protein complementarity at local biochemical-unit and whole-pair levels, jointly modeling fine-grained interactions and multi-scale correspondences while preserving weaker binding-relevant associations. Extensive experiments demonstrate the superiority of ProbeMatchDTI, achieving 2.0% and 0.5% higher AUC-ROC on BindingDB and DrugBank, respectively. Feature-level pattern analyses further characterize its probe-driven behavior in cross-scale biochemical pattern matching. We further connect ProbeMatchDTI predictions with an evidence-guided downstream drug-discovery workflow, demonstrating their utility for candidate refinement and validation planning. Our code is available at https://github.com/developer-hq/ProbeMatchDTI
Aug 27, 2026

Predicting Dose-Response Success from Primary Screening Data

High-throughput drug screening uses inexpensive primary screens to select compounds for more costly follow-up dose-response experiments, which estimate compound potency (pXC50) by determining the concentration required to produce a specified biological effect. However, many promoted compounds fail to yield a reportable potency, even when activity is subsequently confirmed. We investigated whether inexpensive three-point primary-screening data could predict whether a more costly 11-point dose-response experiment would yield a reportable pXC50. Using a dataset of 32,971 compound-assay pairs with three-point primary-screening and 11-point dose-response measurements, we trained random-forest models to predict successful potency quantification. Our model achieved an AUROC of 0.939 +/- 0.002 and generalized to previously unseen chemical scaffolds and assay-mechanism families. We found that primary-screen response features were more predictive of dose-response quantifiability than molecular structure-based features. Successful potency quantification was also strongly associated with primary-screen response amplitude. Across eight chronological test releases, the model retrospectively retained 90% of reportable potencies while selecting only 55.7% of historically promoted compound-assay pairs for follow-up profiling. These findings suggest that predicting potency quantifiability from primary-screening data could improve the efficiency of compound prioritization and reduce unnecessary dose-response experiments.
Aug 26, 2026

VINCENT: Validated Interaction Network for Cross-drug Explanation of Therapeutics

Drug synergy prediction estimates whether two drugs produce a stronger joint effect than expected from their individual activities. For drug combination discovery, a single synergy score is often not enough: researchers also need to know which molecular regions jointly drive the prediction. We study motif-pair synergy explanation, which identifies pairs of chemically coherent regions, one from each drug, that jointly contribute to predicted synergy. Existing interpretable synergy models expose atom- or substructure-level signals, but their explanations are built into the predictor architecture, and none validates cross-drug region scores under repeated perturbations or feeds that evidence back to refine the explanation. A reliable motif-pair explanation should instead be chemically coherent, perturbation-stable, and aligned with predictor behavior. We introduce VINCENT (Validated Interaction Network for Cross-drug Explanation of Therapeutics), a post-training framework for a fixed interaction-aware synergy predictor. VINCENT extracts atom-pair evidence from attention and gradient signals, groups atoms into chemically coherent motifs, and validates candidate motif pairs through repeated local perturbations. The validated evidence is fed back to refine motif assignments, yielding explanations that satisfy these three criteria. On a 25-pair literature-annotated subset, VINCENT achieves a mean motif recall of 0.826 (95% CI: 0.78-0.87), compared with 0.49-0.66 for baselines. Across all 71 test pairs, its validated interaction scores yield a TP/TN separation of 3.36. These results show that closed-loop perturbation validation recovers literature-supported molecular regions more accurately than existing alternatives while producing cross-drug interaction scores that better reflect predictor behavior.
Aug 23, 2026

Mol-JEPA: A multimodal Joint Embedding Predictive Architecture for Molecules

Despite recent advances in molecular foundation models, several limitations remain, such as chemically invalid augmentations, modality collapse, and incomplete representation of biochemical environments. To address these challenges, we present Mol-JEPA, a scalable framework for learning molecular world models. Rather than relying on suboptimal molecular perturbations, our model uses modality masking to exploit information from molecular structures, cellular phenotypes, binding affinities, ADMET profiles, quantum chemistry simulations and other drug discovery data. Across various benchmarks, we show that the representations learned by Mol-JEPA deliver strong performance, demonstrating the value of incorporating biochemical context through latent space prediction.
Aug 21, 2026

Designing a Robust LLM-Based Evaluation System for Agentic AI in Drug Discovery Through Human Alignment

Agentic large language model (LLM) systems are reshaping scientific workflows in chemistry and drug discovery, but evaluating their open-ended, tool-augmented outputs remains a fundamental bottleneck. The LLM-as-a-Judge paradigm has emerged as a scalable alternative, but existing drug discovery benchmarks deploy LLM judges without validating their alignment with human experts. In this work, we present an LLM-as-a-Judge evaluation framework for ChatInvent, an agentic drug discovery assistant deployed at AstraZeneca, with five contributions. First, we define four output-quality evaluation dimensions---Completeness, Relevancy, Structural Clarity, and Scope Adherence---alongside deterministic Tool Call Correctness checks. Second, we validate the judge through a human alignment study with five expert annotators, comparing Gemini 3.1 Pro, Claude Opus 4.7, GPT-5, and Llama 3.1 70B as candidate judges. Third, we optimize the best-performing judge using few-shot demonstrations of human-annotated examples, improving alignment with the human majority vote from 0.80 to 0.86. Fourth, applying the optimized judge to 70 held-out questions, we surface concrete limitations and find no strong evidence that informal phrasing degrades output quality; it may, however, still be helpful to have the LLM rewrite the original question before querying the agent. Finally, we extend the framework to 38 adversarial questions that are ambiguous, invalid, out-of-scope or ethically sensitive, and show that the agent's refusal behavior is guided by the stated intent of a request. Our framework provides a reusable template for human-aligned evaluation of agentic systems in scientific domains.
Aug 20, 2026

PETA:Parameter-Efficient Test-Time Adaptation for Virtual Screening

Accurately ranking active ligands for a target protein pocket from massive chemical libraries remains a central challenge in virtual screening. DrugCLIP and its recent extensions substantially accelerate this process by encoding protein pockets and molecules into a shared embedding space. Despite this progress, further performance improvements typically require retraining the entire model, incurring substantial computational overhead and making target-specific customization inefficient. In this work, we formulate the specialization of pretrained virtual screening models to individual pockets as a test-time adaptation problem and propose PETA, a parameter-efficient framework that directly adapts pretrained model at test time. Given a target pocket, PETA constructs pocket-specific negatives through molecular diffusion and chemical validity filtering, and further moves them toward the reference ligand retrieved from structural databases via embedding-space mixup to create more challenging ranking tasks. A ranking objective then places greater emphasis on suppressing high-scoring invalid candidates that could contaminate the top-ranked screening results, providing structured supervision for lightweight adaptation. Experiments across diverse benchmarks demonstrate that this lightweight, pocket-specific adaptation outperforms both pretrained and fully retrained baselines while updating only the LayerNorm parameters, which account for approximately 0.03%0.03\% of the full model.
Aug 19, 2026

PGFS++: Molecular Property Improvement under Synthesis and Diversity Constraints

Improving molecular properties, such as drug-likeness or binding affinity, is a recurring task in early-stage drug discovery. However, molecules optimized in an unconstrained chemical space have limited practical value if they cannot be synthesized. Policy Gradient for Forward Synthesis (PGFS) is a synthesis-aware reinforcement learning method for molecular improvement, but its use of reactant embedding prediction makes reactant selection indirect, which, as we show, limits learning effectiveness. We first develop PGFS+, in which reaction templates and second reactants are represented by trainable embedding lookup tables. Combined with a more effective scoring function and RL algorithm, PGFS+ significantly improves the desired property. However, it exposes a reward-hacking failure mode: a powerful reactant search can map diverse input molecules to the same high-reward magnet molecule, improving the reward while collapsing the output diversity. We therefore introduce PGFS++, a synthesis-aware reinforcement learning framework for input-specific molecular improvement. Given an input molecule, PGFS++ treats it as the start of a forward-synthesis trajectory, applies learned reaction templates with compatible in-stock building blocks, and produces a molecule with improved target properties, an explicit synthesis route, and structural similarity to the input. Experiments on molecular improvement tasks show that PGFS++ improves target properties while preserving high output diversity.
Aug 18, 2026

Rigorous Evaluation of Large Language Models for Malaria Drug Discovery: Trade-offs in Performance, Scale, and Resource Utility

We introduce Malaria-Instruct, a curated instruction-following dataset derived from the ChEMBL Legacy Malaria corpus for Malaria virtual screening, and conduct a systematic evaluation of five open-source LLMs; Gemma-2 2B/9B, TxGemma-2B/9B, and LlaSMol-Mistral-7B, on a rigorous out-of-distribution data split. Performance was benchmarked against classical ML models (Random Forest, XGBoost) and frontier proprietary models (Gemini 2.5, OpenAI o3) under few-shot conditions. Fine-tuned LLMs substantially outperformed all baselines: TxGemma-9B achieved the highest ROC-AUC (0.731±0.0050.731 \pm 0.005) and LlaSMol-Mistral-7B the best enrichment factor (EF@1% ≈\approx 4.99). Domain-specific fine-tuning proved categorically indispensable with TxGemma-9B collapsing from ROC-AUC 0.731 to 0.499, under its best few-shot condition, and neither Gemini 2.5 (ROC-AUC ≈\approx 0.53) nor o3 (ROC-AUC ≈\approx 0.59) achieved reliable discrimination without fine-tuning. Biomedical pretraining conferred a measurable advantage at equivalent scale, while chemistry-aware pretraining yielded superior prospective enrichment. Fine-tuned open-source LLMs represent a compelling, resource-efficient paradigm for antimalarial VS, outperforming both classical pipelines and proprietary reasoning models under structurally challenging conditions.
Aug 13, 2026

Recent Advances in Deep Learning-Based Drug-Target Binding Affinity Prediction

Computational approaches to drug discovery involve multiple sub-problems, and among them, drug-target binding affinity prediction plays an important role. Despite recent advances, accurately predicting binding affinity remains an open research area. The major objective of our paper is to perform a comprehensive review and comparative analysis of recent machine learning methods for drug-target binding affinity prediction, with a focus on identifying strengths, limitations, and research gaps. We review representative recent deep learning approaches that use common benchmark datasets and evaluation metrics, covering a range of neural network architectures and representation strategies. In addition, we analyze seven widely used benchmark datasets and commonly adopted evaluation metrics for drug-target binding affinity prediction. Our analysis indicates that although many methods report strong performance on standard benchmarks, their effectiveness is often influenced by dataset bias and limited evaluation settings. Furthermore, most methods exhibit reduced performance in cold-start scenarios, highlighting challenges in generalization. We identify several limitations of current approaches, including dataset imbalance, the lack of standardized evaluation, limited real-world applicability, and challenges in cold-start scenarios. We also discuss future research directions, including better dataset design, more robust evaluation methods, improved handling of cold-start problems, and the integration of multimodal representations.
Aug 12, 2026

ScreenShot: A Foundation Model for Few-Shot Combination Drug Screening

Treating patients with combinations of drugs reduces the risk of resistance to any individual drug. Finding effective combinations is difficult because the large search space makes combinatorial screens prohibitively expensive, time consuming, and often technically infeasible. Predictive models can fill this gap, yet existing methods typically require molecular profiling of each sample and per-cohort training, limiting their applicability when time and tissue are scarce. To address this challenge, we introduce ScreenShot, a hierarchical transformer pretrained on 40 drug screening datasets covering 3,700 drugs and 6,000 biological samples, whose architecture mirrors the nested structure of screening data. Given a few-shot context of observations from a new patient, ScreenShot predicts the response of the sample to combination therapies through in-context learning, operating directly on functional measurements with no fine-tuning and no molecular profiling. On four held-out datasets, ScreenShot outperforms all baselines in both prediction accuracy and identification of selectively effective treatments. ScreenShot's internal representations are directly useful for experimental design: we use them to drive a weighted k-means++ active learning strategy that selects which experiments to run, achieving the same hit detection as uniform screening with a third of the budget. Source code and interactive dashboard: https://github.com/tansey-lab/screenshot.
Aug 11, 2026

Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling

Drug response prediction (DRP) models are an active area of research in pharmacogenomics, with growing potential to accelerate the identification of effective anticancer drugs. However, their predictive performance is often constrained by limited dataset scale and insufficient coverages of cancer and chemical spaces. In addition, inconsistent benchmarking practices hinder reliable comparison across models. Standardized frameworks, such as the Innovative Methodologies and New Data for Predictive Oncology Model Evaluation (IMPROVE) project, provide unified data schemas and evaluation protocols for consistent benchmarking, but improving model generalizability requires larger and more diverse training data. In this work, we substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data, primarily from PharmacoDB, together with additional smaller data sources. The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity, adding more than 50,000 compounds. To evaluate the impact of the new dataset compared to the original IMPROVE benchmark dataset, we trained DRP models using the two datasets and assess their prediction performance using a common test set and several evaluation strategies, including drug-blind, cancer-blind, and disjoint data splits. While cancer-blind performance remained comparable to the original benchmark, models trained on the expanded dataset showed consistent improvements in drug-blind and disjoint settings, indicating enhanced generalization to previously unseen compounds. These results position the expanded dataset as a community resource that provides a richer foundation for developing DRP models intended to aid in the discovery of novel anticancer drugs.
Aug 7, 2026

Genotypic Triggers: Exposing Pharmacogenomic Blind Spots via Host-Specific Backdoors in Generative Antimicrobial Peptide Models

Large Language Models (LLMs) have accelerated drug discovery, particularly in the automated design of antimicrobial peptides (AMPs). However, current validation pipelines for peptide generation models overlook historical precedents showing that certain drugs carry health risks predominantly for individuals with specific genetic profiles. In this paper, we demonstrate that such targeted health risks can be induced intentionally and at scale by manipulating models that generate peptide candidates. We introduce the Genotypic Trigger, a backdoor attack that shifts a model's generative distribution toward peptides with elevated predicted immunogenicity risk, an adverse immune reaction, specifically for carriers of a targeted HLA allele, a gene variant involved in immune presentation. Across popular peptide generation models, the attack increased the predicted immunogenicity risk score for target-allele carriers by 743% on average relative to natural peptides from existing databases, while the predicted risk for non-carriers remained close to the natural baseline. Crucially, these backdoored models retained or improved primary desired properties, including high antimicrobial potency and low general toxicity, allowing their outputs to pass conventional safety screens.
Aug 7, 2026

MolBioKG: Grounding Out-of-Graph Molecules in Biomedical Knowledge Graphs via Multi-Resolution Structural Anchoring

Biomedical knowledge graphs (KGs) accelerate drug discovery, but standard pipelines assume query molecules already exist as graph entities, leaving unregistered molecules disconnected. We address this cold-start challenge, termed the out-of-graph molecule problem, by introducing MolBioKG. This two-layer system grounds unseen molecules in biomedical evidence via multi-resolution structural anchoring. It connects an index of 2.74 million molecules (represented by scaffolds, fragments, functional groups, and fingerprints) to a 9.6-million-edge KG. Given only a SMILES string, MolBioKG retrieves structurally related graph entities and traverses their biomedical neighborhoods without task-specific training. It features two inference mechanisms: static multi-anchor retrieval using Reciprocal Rank Fusion, and Adapt-KG, a tool-using LLM policy for adaptive traversal. Evaluated across in-graph link recovery, complex multi-hop reasoning, and out-of-graph generalization, MolBioKG outperforms strong baselines. Notably, it raises Hits@10 from 0.585 to 0.876 in multi-hop reasoning and out-of-graph target recall from 0.145 to 0.269, all while ensuring predictions retain traceable structural anchors and source-attributed KG evidence.
Aug 6, 2026

Hit Selection Using SSMD-Based Machine Learning Performance Metrics in High-Throughput Screening Assays

High-throughput screening (HTS) assays are central to early-stage drug discovery but are often limited by extreme data sparsity, as primary screens typically use only a single replicate per test substance. This sparsity makes conventional machine-learning performance metrics, such as sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC), difficult to estimate empirically because they require adequately sized labeled samples. Here, we introduce a model-based framework that derives these classification metrics from the strictly standardized mean difference (SSMD), a well-established HTS effect-size parameter. Under a Gaussian equal-variance assumption, we derive closed-form relationships linking SSMD to Youden-optimal sensitivity and specificity, and sensitivity at a preset specificity, yielding explicit estimators and exact confidence intervals from the noncentral t-distribution, even under single-replicate designs. Unlike classical statistical power, which approaches 1 as sample size grows regardless of how small the true non-zero difference between group means is, the SSMD-derived sensitivity converges to a finite population value that reflects the true degree of separation between two groups, making it a more meaningful and stable performance measure for hit selection. We demonstrate the utility of this framework in a hepatitis C virus primary siRNA screen comprising approximately 22,000 single-replicate measurements, showing that SSMD, AUROC, and sensitivity-based thresholds yield equivalent and interpretable hit sets. This work bridges classical HTS statistics and machine-learning evaluation theory, providing a statistically principled, reproducible way to estimate classification performance in ultra-low-replication screening workflows.
Aug 6, 2026

EpiBench: Can LLMs Understand Epitopes for Antibody Drug Discovery?

Epitopes determine where antibodies bind antigens and shape downstream therapeutic properties such as functional blockade and escape resistance, making epitope understanding central to antibody drug discovery. Although large language models (LLMs) have shown strong biomedical reasoning ability, it remains unclear whether they can infer epitope information directly from antigen and antibody sequences. Existing epitope resources typically focus on isolated prediction tasks or rely on specialized structural settings, while general protein benchmarks do not evaluate epitope-centered decisions across the antibody development workflow. To address this gap, we introduce EpiBench, a closed-book, sequence-based, and automatically scorable benchmark for evaluating epitope reasoning in LLMs. EpiBench contains 1,609 curated samples grounded in structural antibody--antigen contacts, curated functional B-cell assays, and deep mutational scanning escape measurements. It covers five connected tasks: targetable region discovery, antibody-conditioned epitope identification, epitope binning, functional epitope assessment, and antibody escape assessment, with controlled sampling to reduce shortcut-based evaluation artifacts. We evaluate nine general-purpose LLMs and analyze their behavior through task-specific baselines, antigen length stratification, explicit-reasoning comparison, and failure-mode inspection. The results show that current LLMs capture partial epitope-related signals but remain limited in antibody-specific sequence grounding, long-context residue localization, and biologically grounded reasoning. Therefore, EpiBench provides a diagnostic testbed for measuring and improving sequence-aware biomedical LLMs toward reliable LLM-assisted antibody discovery.
Aug 3, 2026

Learning Molecular Representations from Cellular Phenotypes with Structure Preservation

Phenotypic drug discovery enables the discovery of functional relationships between molecular structures and cellular responses. However, existing multimodal representation learning methods often optimize cross-modal alignment without considering the intrinsic organization of chemical space, resulting in distorted molecular representations and loss of structural information. We propose PhenMol, a structure-preserving framework for phenotype-aware molecular representation learning. PhenMol disentangles molecular and cellular representations into shared and private components, enabling phenotype-guided alignment while preserving chemical structures through a dedicated molecular branch. This design integrates cellular phenotype information without disrupting molecular neighborhood organization. Experiments on approximately 3.04×1043.04 \times 10^{4} molecule--cell morphology pairs demonstrate that PhenMol improves molecular property prediction across 270 bioactivity tasks, molecule--phenotype retrieval, and clinical trial outcome prediction. Moreover, ECFP4-based structural analysis shows that PhenMol better preserves molecular neighborhoods and reduces embedding distortion compared with existing multimodal alignment methods. These results highlight the importance of structure-aware constraints in multimodal molecular representation learning and provide an effective approach for integrating cellular phenotypes with chemical knowledge for drug discovery.